Home > Boards > US Listed > Biotechs > Actinium Pharmaceuticals, Inc. (ATNM)

While clinical trials results seem encouraging

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Fosco1 Member Profile
Member Level 
Followed By 15
Posts 402
Boards Moderated 0
Alias Born 10/09/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 5:01:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2020 4:18:50 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2020 4:16:20 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/23/2020 5:02:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/7/2020 5:02:07 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/7/2020 5:01:10 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/17/2020 6:21:29 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:23:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:22:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:19:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:18:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2020 5:07:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:05:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:05:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:04:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:03:59 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/12/2020 6:01:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:32:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 5:11:05 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 7/13/2020 5:10:51 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/30/2020 6:32:21 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/18/2020 4:40:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/18/2020 4:32:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 4:37:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 4:22:08 PM
Fosco1 Member Level  Tuesday, 11/10/20 02:04:27 PM
Re: None
Post # of 2551 
While clinical trials results seem encouraging

Let us focus on Phase III Iomab-B Sierra trial and answer simple questions.

Will latest analysis performed on 75% of the population result in early termination for efficacy ?

The answer is NO, otherwise the company would have said so. Let us be clear on this.

So here comes the next question. What will be the outcome of the ad'hoc interim going forward for this 75% population ?

There can be two :
- Either the trial will continue till completion
- Either the IDMC will recommend the trial to stop

Can the IDMC recommend the trial to stop and for which reason ?

The answer is YES it can, for lack of power in the control arm

Let's look at the control arm

There were 5 patients evaluable (for primary endpoint) in the control arm at 50% interim VS 29 in the TEST arm (N=37+38)

There were 7 patients evaluable in the control arm VS 44 in the TEST arm at the 75% interim (N=53+53) => This is clearly not enough to terminate this trial at this point

How many evaluable patients will there when all 150 patients achieve treatment ? That is the outcome of the incoming ad'hoc meeting, it might be something like this :

N=75 TEST N=75 CONTROL
around 60- 62 patients evaluable in TEST and around 10 in Control

Clearly the IDMC might conclude through a conditional power analysis that there will never be enough evaluable patients in the control arm and recommend the study to be terminated for futility as designed as such. It might also recommend to continue till completion, but still the trial could complete without achieving enough power because of the control arm.

Thus Actinium management will need to talk to FDA to amend this trial and change the SAP (for instance to use historical survival instead of a control arm) or redo another better designed trial. I see this as very likely despite the encouraging results showed so far, whose gibberish language for the average investor is not showing clearly this reality. Talk to the FDA will take a lot of time and will delay things. The market will not accept this phase III news as good news

Sorry, but this is my understanding of the facts regarding Sierra Phase III Trial, but I guess we will know soon enough what is the outcome before the end of the year.


Fosco



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences